Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

37.5%

3 terminated/withdrawn out of 8 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
4(50.0%)
Phase 3
2(25.0%)
Phase 1
2(25.0%)
8Total
Phase 2(4)
Phase 3(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT03337503Phase 2Terminated

Safety and Efficacy of Medical Cannabis Oil in the Treatment of Patients with Chronic Pain

Role: collaborator

NCT04042545Phase 2Unknown

Safety and Efficacy of Inhaled Cannabis For the Uncontrolled Pain Relief in Patients With Advanced Cancer

Role: lead

NCT03564548Phase 2Unknown

Inhaled Cannabinoids Versus Immediate-release Oral Opioids for the Management of Breakthrough Cancer Pain

Role: lead

NCT04001010Phase 3Suspended

Safety and Efficacy of Inhaled Synthetic THC/CBD for Improving Physical Functioning and for Modulating Cachexia Progression in Patients With Advanced Cancer and Associated Cachexia

Role: lead

NCT04461756Phase 1Completed

Safety and Pharmacokinetics of Vaped Cannabis in Healthy Volunteers

Role: lead

NCT04314804Phase 1Completed

Safety and Pharmacokinetics of Smoked Cannabis in Healthy Patients

Role: lead

NCT03763851Phase 2Terminated

Cannabis Oil and Radiation Therapy for the Management of Pain

Role: lead

NCT03339622Phase 3Terminated

Safety and Efficacy of Smoked Cannabis for Improving Quality of Life in Advanced Cancer Patients

Role: lead

All 8 trials loaded